What is your treatment of choice in ALK-positive lung adenocarcinomas that have progressed on alectinib with resistance mutations that are not G1202R?  

Do you choose Lorlatinib or brigatinib? Or do you try to add chemotherapy to alectinib?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice